Long COVID Treatment Breakthrough- From Symptoms to Science-Backed Solutions
"Leronlimab for Immune Modulation
Leronlimab, a CCR5-binding humanized IgG4 monoclonal antibody, has emerged as a candidate for addressing immune dysregulation in long COVID. In an exploratory trial involving 55 individuals, weekly subcutaneous doses of leronlimab (700 mg) were administered for 8 weeks. Intriguingly, researchers observed significantly increased blood cell surface CCR5 levels from baseline to week 8 among leronlimab-treated participants who experienced symptom improvement, but not in non-responders or placebo recipients [21].
This finding suggests an unexpected mechanism whereby leronlimab may normalize abnormal immune downmodulation rather than persistent immune activation. In fact, leronlimab treatment was associated with increases in key adaptive immune cell populations including T cells [21]. Furthermore, preliminary results indicated numerically higher percentages of participants with reduced symptom scores across 18 of 24 COVID symptoms when compared with placebo, yet these differences did not reach statistical significance in this small exploratory study [22]."
https://globalrph.com/2025/12/long-covid-trea...solutions/
18
1
